OVID - ovidrx.com Debt to Book Capitalization Ratio

Graphic logo of ovidrx.com (OVID)

Ovid Therapeutics Inc. (OVID) is scaling its small molecule development to combat epilepsy, funding R&D through licensing royalties. The current debt-to-book capitalization ratio illustrates financial stability, where the value of 0.06 expresses the metric level. This approach to asset structure minimizes scientific risks when creating therapies for patients with severe brain pathologies.

Ovid Therapeutics Inc (OVID) - Debts to Book Value from 07/04/2022 to 10/29/2026
Original product of ovidrx.com

Assessing an issuer's financial stability is critical for objective portfolio management. This indicator compares total liabilities to the market value of equity to measure the level of credit risk. By analyzing the company's current debt-to-market capitalization ratio, an investor determines the asset's margin of safety. An increase in this ratio signals excessive leverage. For Ovid Therapeutics Inc. (OVID), this metric indicates the ability to fund the market launch of its neurotherapy prior to the onset of mass sales.

Competitors of Ovid Therapeutics Inc. (OVID)

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|XENE (Xenon Corp) - Debts to Book Value|Debt to Book Capitalization Ratio VKTX (Viking Therapeutics)|Debts to Book Value supernus.com (SUPN)|Debt to Book Value Catalyst Pharmaceuticals, Inc. (CPRX)|Debt to Book Capitalization Ratio Denali (DNLI)|Debts to Book Capitalization HRMY|Debts to Net Assets Biohaven Corp BHVN|Amylyx Pharmaceuticals (AMLX) - Debts to Book Capitalization|trevitherapeutics.com (TRVI) - Debt to Book Value Ratio|Debt to Book Value Praxis Precision Medicines, Inc. PRAX|Debt to Net Assets Ratio Anavex|CeriBell Corp (CBLL) - Debt to Book Value|Debt to Book Capital prothena.com|Alector, Inc. (ALEC) - Debts to Book Capitalization|Debt to Net Assets Ratio annexonbio.com (ANNX)|OMER: Debts to Book Capitalization|Neurogene Inc - Debts to Book Value|Debt to Book Capitalization Ratio AC Immune Corp (ACIU)|VYGR - Debt to Net Assets Ratio|NMRA: Debts to Book Capitalization|SCLX (scilexholding.com) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Tevogen Bio TVGN|Debts to Book Capitalization Ratio Alpha Cognition Corp|Cognition Therapeutics - Debts to Book Capitalization|Debts to Book Value Inhibikase Pharma IKT|Debt to Book Value SAVA (Cassava Sciences, Inc.)|ASRT - Debts to Book Capitalization|Debt to Book Value Coya COYA|VTGN - Debt to Book Capital|Acumen Pharma - Debts to Book Capitalization|CervoMed Corporation (CRVO) - Debts to Net Assets|Debts to Book Capitalization ATHE|Debt to Book Value CLNN|PEPG (PepGen Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets Jupiter Neurosciences, Inc. JUNS|Debt to Book Value Relmada|Debt to Net Assets Ratio Annovis Bio Corporation ANVS|Debts to Book Capitalization GRCE (Grace Tx)|AIFF: Debts to Net Assets|Debt to Book Capitalization Ratio anewmeds.com|NeuroSense Therapeutics Ltd. (NRSN) - Debt to Book Value Ratio|Debts to Book Capitalization RVPH|Debt to Book Value MetaVia, Inc. (MTVA)|NRXS (NeurAxis, Inc.) - Debt to Book Value|Debts to Net Assets HSDT (heliusmedical.com)|PASG: Debt to Book Capitalization Ratio|NEUP - Debts to Book Value|NERV - Debt to Book Value|ATHA - Debt to Book Capitalization Ratio|Addex Therapeutics - Debts to Book Capitalization|Alzamend Neuro (ALZN) - Debts to Net Assets|Debts to Book Capitalization Cyclerion Therapeutics Inc. (CYCN)|Debt to Book Value Ratio PTIX|Debt to Book Capitalization Ratio Pasithea Therapeutics KTTA|Debt to Book Value Ratio cortigent.com (CRGT)|ATXI: Debts to Book Capitalization|BCLI - Debts to Book Value|Cara Therapeutics - Debt to Book Value|CHRO: Debts to Book Capitalization|Debt to Book Capitalization Ratio eliemtx.com ELYM|ITCI (Intra-Cellular Therapies, Inc.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio LBPH (Longboard Pharmaceuticals)|Debts to Book Value MRNS|NKGen Biotech - Debt to Book Capitalization Ratio|Debts to Book Value NeuroBo Pharmaceuticals Inc NRBO|Debt to Book Value Sage Therapeutics, Inc SAGE|Debt to Book Capitalization Ratio Synaptogenix, Inc SNPX|Debts to Book Capitalization TRVN (Trevena, Inc.)|VIGL - Debts to Net Assets|Debts to Book Capitalization Anew Medical|Debt to Book Value Ratio Cerevel Therapeutics Inc